20 December 2019 
EMA/CHMP/3022/2020  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed 
completed paediatric investigation plan 
Medicinal product  
Dacogen/ decitabine 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing authorisation holder (MAH): 
Name and address of the MAH: 
Janssen-Cilag International N.V. 
Turnhoutseweg 30 
B-2340 Beerse 
Belgium 
Procedure  
Procedure number: 
EMEA/H/C/0002221/IB/0041 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the PIP for DACOGEN (P/0234/2017) consisted of 5 studies, 4 non-clinical studies (PIP Measures 1 
to 4) and 1 clinical study (PIP Measure 5):  
Reports of compliance were adopted by the PDCO on 15 July 2011 for PIP Measure 1 and on 18 
October 2019 for PIP Measures 2 to 5.   
Results of the PIP measures were assessed by the CHMP at time of the marketing authorisation 
application (PIP Measure 1), the renewal application (PIP Measures 2 to 4) and the variation 
procedure II-33 (PIP Measure 5). 
Results from the study conducted in the paediatric population have been reflected in the EUPI as 
part of the procedure EMEA/H/C/002221/II/33.  
The outcomes of the compliance checks with PIP are provided within this application, as follow:  
- Partial compliance check (PIP Measure 1) granted on the 15 July 2011 
- Full compliance check (PIP Measure  2-5) granted on the 18 October 2019 
-the Summary of Product Characteristics adopted by CHMP already reflected the results of studies 
conducted in compliance with this agreed paediatric investigation plan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
